171 related articles for article (PubMed ID: 6329237)
1. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Casals-Stenzel J; Buse M; Wambach G; Losert W
Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
[TBL] [Abstract][Full Text] [Related]
2. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone antagonists. 1. Synthesis and activities of 6 beta,7 beta:15 beta,16 beta-dimethylene steroidal spirolactones.
Nickisch K; Bittler D; Casals-Stenzel J; Laurent H; Nickolson R; Nishino Y; Petzoldt K; Wiechert R
J Med Chem; 1985 May; 28(5):546-50. PubMed ID: 3989815
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of new steroidal aldosterone antagonists. Comparison of the affinity for mineralocorticoid receptors in vitro and the antialdosterone activity in vivo.
Wambach G; Casals-Stenzel J
Biochem Pharmacol; 1983 May; 32(9):1479-85. PubMed ID: 6222738
[TBL] [Abstract][Full Text] [Related]
5. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
[TBL] [Abstract][Full Text] [Related]
6. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo M; Joss U; Ramjoué HP; Whitebread SE; Haenni H; Schenkel L; Kraehenbuehl C; Biollaz M; Grob J; Schmidlin J
J Pharmacol Exp Ther; 1987 Feb; 240(2):650-6. PubMed ID: 2949071
[TBL] [Abstract][Full Text] [Related]
7. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
8. SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.
Cutler GB; Sauer MA; Loriaux DL
J Pharmacol Exp Ther; 1979 Apr; 209(1):144-6. PubMed ID: 430374
[TBL] [Abstract][Full Text] [Related]
9. [Direct action of mineralocorticoid antagonists on biosynthesis of aldosterone: comparative activities of several new compounds].
Netchitailo P; Perroteau I; Delarue C; Leboulenger F; Capron MH; Vaudry H
Can J Physiol Pharmacol; 1983 Jan; 61(1):23-8. PubMed ID: 6301660
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro.
Weindel K; Lewicka S; Vecsei P
Arzneimittelforschung; 1991 Sep; 41(9):946-9. PubMed ID: 1796922
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of a new antialdosterone compound, prorenone.
Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Corvol P
Endocrinology; 1979 Apr; 104(4):1194-200. PubMed ID: 436757
[TBL] [Abstract][Full Text] [Related]
12. Experimental studies on the endocrine side effects of new aldosterone antagonists.
Nishino Y; Schröder H; el Etreby MF
Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852
[TBL] [Abstract][Full Text] [Related]
13. Interference of C17-spirosteroids with late steps of aldosterone biosynthesis. Structure-activity studies.
Weindel K; Lewicka S; Vecsei P
Arzneimittelforschung; 1991 Oct; 41(10):1082-91. PubMed ID: 1799390
[TBL] [Abstract][Full Text] [Related]
14. Affinity of 18,19-dihydroxydeoxycorticosterone and 18-hydroxy-19-nor-deoxycorticosterone to aldosterone receptor and their mineralocorticoid activity.
Okamoto M; Momoi K; Yamano T; Nakamura M; Odaguchi K; Shimizu T; Okada T; Terasawa T
Biochem Int; 1983 Dec; 7(6):687-94. PubMed ID: 6237653
[TBL] [Abstract][Full Text] [Related]
15. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships.
Paris J; Botella J; Fournau P; Bonnet P; Thevenot R
J Pharmacol Exp Ther; 1987 Oct; 243(1):288-91. PubMed ID: 2822901
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated.
Ge RS; Dong Q; Sottas CM; Latif SA; Morris DJ; Hardy MP
Mol Cell Endocrinol; 2005 Nov; 243(1-2):35-42. PubMed ID: 16188378
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of aldosterone in normal subjects by Ro 12-2503 and spironolactone.
Dux S; Rosenfeld J; Cocco G; Chu D; Gasser DF
Arzneimittelforschung; 1982; 32(2):164-9. PubMed ID: 7199923
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
Kamata S; Matsui T; Haga N; Nakamura M; Odaguchi K; Itoh T; Shimizu T; Suzuki T; Ishibashi M; Yamada F
J Med Chem; 1987 Sep; 30(9):1647-58. PubMed ID: 3040999
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone antagonists. 2. New 7 alpha-(acetylthio)-15,16-methylene spirolactones.
Nickisch K; Bittler D; Laurent H; Losert W; Casals-Stenzel J; Nishino Y; Schillinger E; Wiechert R
J Med Chem; 1987 Aug; 30(8):1403-9. PubMed ID: 3612688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
